Prolongation and expansion of agreement with TRT Innovations ApS

Today, the 7 October, 2020, Curasight A/S (“Curasight” or the “Company”) has entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.

In addition to the Company's patent licensing agreement of December 12, 2019, the Company has prolonged the agreement with TRT Innovations that ensures that the Company can continue to use TRT Innovations patent rights for brain, prostate and colorectal cancer. In addition, the agreement also provides an option for the Company to use the patent rights beyond these indications.

The option can be exercised until 31 January 2024.

The agreement supports the Company's strategy and does not imply a change in future expectations in relation to what is described in the prospectus. Andreas Kjær, board member and shareholder in Curasight, is also a founder and shareholder of TRT Innovations.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60

E-mail: uk@curasight.com www.curasight.com

This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 7 October, 2020.

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.